Match!
Alba Carreras
Sahlgrenska University Hospital
7Publications
4H-index
95Citations
Publications 7
Newest
#1Alba Carreras (Sahlgrenska University Hospital)H-Index: 4
#2Luna Simona PaneH-Index: 2
Last.Marcello MarescaH-Index: 6
view all 20 authors...
Background Plasma concentration of low-density lipoprotein (LDL) cholesterol is a well-established risk factor for cardiovascular disease. Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9), which regulates cholesterol homeostasis, has recently emerged as an approach to reduce cholesterol levels. The development of humanized animal models is an important step to validate and study human drug targets, and use of genome and base editing has been proposed as a mean to target diseas...
1 CitationsSource
#1Stephen Lee (UCLA: University of California, Los Angeles)H-Index: 27
#2Christina Priest (UCLA: University of California, Los Angeles)H-Index: 1
Last.Cynthia Hong (UCLA: University of California, Los Angeles)H-Index: 31
view all 30 authors...
Liver X receptors limit cellular lipid uptake by stimulating the transcription of inducible degrader of the low-density lipoprotein receptor (IDOL), an E3 ubiquitin ligase that targets lipoprotein receptors for degradation. The function of IDOL in systemic metabolism is incompletely understood. Here we show that loss of IDOL in mice protects against the development of diet-induced obesity and metabolic dysfunction by altering food intake and thermogenesis. Unexpectedly, analysis of tissue-specif...
Source
#1Alba Carreras (Sahlgrenska University Hospital)H-Index: 4
#2Fredrik Bäckhed (UCPH: University of Copenhagen)H-Index: 75
While the commensal microbiota is considered an important regulator of immunity and metabolism, the mechanisms controlling the interplay between diet, cytokine signaling, and the microbiota in atherosclerosis remains unknown. In this issue of Immunity, Fatkhullina et al. (2018) demonstrate that interlukin-23-22 axis regulates diet-induced atherosclerosis by repressing pro-atherogenic microbiota.
Source
#1Ara Koh (Sahlgrenska University Hospital)H-Index: 2
#2A. Molinaro (Sahlgrenska University Hospital)H-Index: 5
Last.Fredrik Bäckhed (UCPH: University of Copenhagen)H-Index: 75
view all 18 authors...
Summary Interactions between the gut microbiota, diet, and the host potentially contribute to the development of metabolic diseases. Here, we identify imidazole propionate as a microbially produced histidine-derived metabolite that is present at higher concentrations in subjects with versus without type 2 diabetes. We show that imidazole propionate is produced from histidine in a gut simulator at higher concentrations when using fecal microbiota from subjects with versus without type 2 diabetes ...
33 CitationsSource
#1Pinar Akcakaya (AstraZeneca)H-Index: 3
#2Maggie L. Bobbin (Harvard University)H-Index: 4
Last.J. Keith Joung (Harvard University)H-Index: 62
view all 22 authors...
CRISPR–Cas genome-editing nucleases hold substantial promise for developing human therapeutic applications1–6 but identifying unwanted off-target mutations is important for clinical translation7. A well-validated method that can reliably identify off-targets in vivo has not been described to date, which means it is currently unclear whether and how frequently these mutations occur. Here we describe ‘verification of in vivo off-targets’ (VIVO), a highly sensitive strategy that can robustly identi...
48 CitationsSource
#1Pinar Akcakaya (AstraZeneca)H-Index: 3
#2Maggie L. Bobbin (Harvard University)H-Index: 1
Last.J. Keith Joung (Harvard University)H-Index: 62
view all 22 authors...
CRISPR-Cas genome-editing nucleases hold substantial promise for human therapeutics but identifying unwanted off-target mutations remains an important requirement for clinical translation. For ex vivo therapeutic applications, previously published cell-based genome-wide methods provide potentially useful strategies to identify and quantify these off-target mutation sites. However, a well-validated method that can reliably identify off-targets in vivo has not been described to date, leaving the q...
4 CitationsSource
#1Amy Warner (AstraZeneca)H-Index: 1
#2Ann Kjellstedt (AstraZeneca)H-Index: 9
Last.Daniel Lindén (AstraZeneca)H-Index: 19
view all 8 authors...
Activation of brown adipose tissue (BAT) and browning of white adipose tissue (WAT) present potential new therapies for obesity and type 2 diabetes. Here, we examined the effects of β3-adrenergic stimulation on tissue-specific uptake and storage of free fatty acids (FFA) and its implications for whole-body FFA metabolism in diet-induced obese rats using a multi-radiotracer technique. Male Wistar rats were high fat-fed for 12 weeks and administered β3-agonist CL316,243 (CL, 1 mg/kg/day) or saline...
9 CitationsSource
1